



2019

THE GENEVA FOUNDATION
The future of military medicine today

Annual Report

Notable Achievements of 2019



MIRROR program launches

Geneva's \$15M Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) program at Uniformed Services University (USU) provides infrastructure, operational, and research support to advance the treatment for service members with non-combat related musculoskeletal injuries.

MIRROR supports 26 studies, impacting approximately 19,940 beneficiaries worldwide

MIRROR's premier steering committee develops 38 validated processes to standardize care guidelines for the 11 most common rehabilitations related to shoulder, hip, knee, and foot/ankle, activates the 14 initial MIRROR projects with 80 patients recruited, hosts five symposiums, and submits ten grant applications.





4D Bio³ Program provides regenerative medicine and biomaterial training to build the future of military medicine

4D Bio³ scientists give lectures to front line military members at the U.S. Military Academy at West Point. The program's first Cadet interned and completed a rotation at the 4D Bio³ Lab, culminating in a poster presentation.

4D Bio³ makes groundbreaking 3D bioprinting and biofabrication advancements

Geneva's 4D Biofabrication, Bioprinting and Biomaterials (4DBio³) Program successfully bioprints medical products, including biologics, in an austere military environment to advance future treatments for deployed warfighters.



Pipeline of federal grant applications over \$159M

Geneva's Grants and Contracts Department submits 141st proposal of the year totaling \$159,330,080 in submissions just in 2019 alone.

FDA approves first vaccine for Ebola

Led by Geneva researcher and employee Dr. Amy Shurtleff, Ervebo, the first vaccine to treat Ebola, was approved.




Traumatic Brain Injury (TBI) research grant received

Geneva collaborates with CIRCULOGENE on a research grant with the DoD to assess traumatic brain injuries led by Geneva researcher and employee Dr. Andriy Batchinsky, Brooks City Base.

Cooperative Agreement issued for antimicrobial Blue light (aBL) therapies

USU issues a Cooperative Agreement to Geneva to investigate the efficacy of aBL in combating infections at the implant site for osseointegrated implant technology.




Geneva-Jonas Scholarship recipients at USU spearhead nursing research - Ph.D. candidates Ms. Lisa Perla and CDR Melissa R. Trancoso strive to improve leadership in health care and address obesity among service members respectively.



Geneva is awarded contract to manage TSNRP - The Triservice Nursing Research Program (TSNRP) at USU has supported rigorous military nursing research to optimize the health of military members since 1990.



Researcher of the Year Award - Senior Nurse Scientist at Madigan Army Medical Center MAJ (Ret.) Mary McCarthy, Ph.D. receives the 2018 Researcher of the Year award for her 25+ years of nursing research expertise focused on the overall wellness, optimized performance, and readiness of service members.



The L.T. Murray Foundation funds Geneva's 1st direct grant award at Joint Base Lewis-McChord - Madigan Army Medical Center researchers, Capt. Daniel Lammers, M.D. and Lt. Col. Matthew Eckert, M.D., receive funding for their research program titled, "Combating Ischemia Reperfusion Injury from Traumatic Injury Requiring Occlusion of the Aorta via Adenosine, Lidocaine, and Magnesium".

By the Numbers

490+
RESEARCH PROGRAMS
WORLDWIDE

240+
PRINCIPAL
INVESTIGATORS

550
EMPLOYEES WORLDWIDE
(17% CORPORATE 83% PROGRAMMATIC)

45+
PARTICIPATING
SITES

225+
SPONSORS &
COLLABORATING PARTNERS

\$55.9
GRANT, CONTRACT,
AND AWARD REVENUE

35+
RESEARCH AREAS

From the President & CEO and Chair of the Board of Directors

As we publish this 2019 report, it is important to address the turmoil related to the COVID-19 pandemic the world is facing at the current time. The Geneva Foundation, like every other entity, is coping with the challenges of 2020. This annual report captures our very successful past year and reminds us that in these trying times, Geneva is managing for the long term.

As we reflect on 2019, The Geneva Foundation has much to celebrate. Thanks to the dynamic, engaged leadership of our Board members, the commitment of our dedicated employees, and the expertise of our diverse network of sponsors and collaborators, Geneva has continued to tackle the military's most urgent medical research needs with groundbreaking advancements across the globe.

This past year saw the first vaccine approved by the FDA for Ebola virus, a tremendous achievement made by our infectious diseases experts at the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID). Geneva's 4D Biofabrication, Bioprinting, and Biomaterials (4DBio³) program successfully printed medical products, including biologics, in an austere military environment to advance future treatments for deployed warfighters. We also saw marked progress in rehabilitative medicine in Geneva's Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) program which supported 26 studies with the potential to impact approximately 19,940 beneficiaries.

The magnitude of Geneva's growing portfolio of research programs and collaborations has inspired our organization to continue to reach new heights and serve as an accelerator of innovation worldwide. Geneva is engaged in initiatives that will ultimately transform how we serve our mission to advance critically important medical research within the U.S. military. As we move forward together, we do so with a renewed strategic focus and desire to build even stronger collaborations by leveraging our 26 years of scientific, technical, and program management expertise and successes.

We are more enthusiastic than ever about progress with first-class partnerships. Geneva's continued engagement with leaders within the Department of Defense (DoD), Defense Health Agency (DHA), and National Institutes of Health (NIH) has enabled us to further discussions and advancements leading to a greater collective impact on how we approach military medicine today. Geneva's growing partnerships with academia, especially the Uniformed Services University (USU), industry partners, including small businesses, and principal investigators have elevated opportunities to address urgent global health needs.


This past year has been remarkable as Geneva continues to expand and achieve its important mission, but we could not have reached new heights without the dedication and contributions of our research teams, partners, employees, and supporters. Thanks to your tireless commitment, Geneva is well-positioned and eager for what the future holds.

Here's to another noteworthy year!



Elise W. Huszar, MBA, President and CEO

Major General (Ret.) Frank Scoggins, Chair of the Board of Directors


Geneva's top 5 largest awards funded in 2019 totaled \$119M



GENEVA'S TOP 15 RESEARCH AREAS BY FUNDING



2019 Financials



Statement of Revenue & Expenditures 2019

(Rounded to the nearest thousand)

Total Grant, Contract, and Other Award Revenue	\$55,938,475
Grant	\$31,636,422
Contract	\$21,899,095
Other Award Revenue	\$2,402,958
Program Expenses	\$47,892,929
Net Income from Grants, Contracts, and Awards	\$8,045,546
Support Services	
General and Administrative	\$8,240,252
Fund Development	\$100,953
Total Support Services	\$8,341,205
Total Other Income (Loss)	\$78,342
Increase (decrease) in net assets	(\$217,317)
Unrestricted Net Assets	
Beginning of Year	\$4,770,543
End of Year	\$4,553,226

2019 REVENUE TO COSTS

